SCHEMBL3596903

SCHEMBL3596903

Cc1ccc(-c2ccc3c(-c4cncnc4)nn(CC(=O)NCCN(C)C4CCCCC4)c3c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.40
MAPK1 P28482 3/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 3/20 0.39
THRB P10828 1/20 0.39
TSHR P16473 5/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 5/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
CYP2D6 P10635 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
GAA P10253 1/20 0.36
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604327 0.91 KDM4E (0.41) KDM4EMAPK1USP2POLBTHRB
SCHEMBL3605304 0.90 THRB (0.47) KDM4EMAPK1USP2POLBTHRB
SCHEMBL13115657 0.86 KDM4E (0.45) KDM4EMAPK1USP2POLBTSHR
SCHEMBL3596908 0.85 POLB (0.40) KDM4EMAPK1POLBTHRBTSHR
SCHEMBL14396904 0.85 KDM4E (0.42) KDM4EMAPK1USP2POLBTSHR
SCHEMBL13115712 0.84 KDM4E (0.38) KDM4EMAPK1USP2POLBTHRB
SCHEMBL3586854 0.81 KDM4E (0.42) KDM4EMAPK1USP2POLBTSHR
SCHEMBL3594491 0.76 KDM4E (0.42) KDM4EUSP2POLBTSHRHSD17B10
SCHEMBL3604329 0.76 POLB (0.41) KDM4EMAPK1POLBTHRBTSHR
SCHEMBL13115590 0.75 ATM (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 KDM4E 4801/4885MAPK1 1264/4885USP2 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.